Drug Safety and Surveillance: the Case of Avandia

Loading...
Thumbnail Image
Penn collection
Issue Briefs
Degree type
Discipline
Subject
Funder
Grant number
Copyright date
Distributor
Author
Margolis, David Joel
Strom, Brian L
Contributor
Abstract

A year ago, a meta-analysis published in The New England Journal of Medicine sounded alarms about the cardiovascular safety of the popular diabetes drug Avandia (rosiglitazone). The study caused both policymakers and the public to question the Food and Drug Administration’s ability to ensure the safety of drugs brought to the marketplace, and evoked memories of Vioxx, the painkiller withdrawn from the market in 2004 because of its link to heart attacks. A year after the Avandia story broke, this Clinical Brief revisits the controversy, summarizes a new study of the cardiovascular safety of diabetes drugs, and analyzes the policy implications for the drug approval process.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2008-01-01
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation
Collection